Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KEAP1 inhibitor (Vividion Therapeutics, immunology)
- Development stage
- Preclinical
- Lead developer
- Vividion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vividion Therapeutics is developing an orally bioavailable small molecule KEAP1 inhibitor for the treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Discovered via a proprietary covalent chemoproteomics platform, the compound works by inhibiting Kelch-like ECH-associated protein 1 (KEAP1). This inhibition prevents the ubiquitination and degradation of Nuclear factor erythroid 2-related factor 2 (NRF2), allowing NRF2 to translocate to the nucleus and upregulate the expression of antioxidant and anti-inflammatory genes. Preclinical studies have demonstrated that this program can significantly inhibit inflammatory cytokines and chemokines while promoting epithelial healing, aiming to provide a disease-modifying effect in chronic inflammatory conditions.
- Other names
- KEAP1 inhibitor (Vividion Therapeutics)
02
Targets
KEAP1 (Kelch-like ECH-associated protein 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on KEAP1 inhibitor (Vividion Therapeutics, immunology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KEAP1 inhibitor (Vividion Therapeutics, immunology).